Dirk Schadendorf

Jan 14, 2025 | tandfonline.com | Dirk Schadendorf |Reinhard Dummer |Keith T Flaherty |Caroline Robert

Plain Language SummaryWhat is this summary about? This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma. What were the results?

Jun 5, 2024 | digitalcommons.library.tmc.edu | Danny Rischin |Nicole Basset-Seguin |Dirk Schadendorf |Samantha Bowyer

BACKGROUND: Cemiplimab (LibtayoMETHODS: In this open-label, phase II trial (ClinicalTrials.gov identifier NCT02760498), the cohort of patients ≥18 years old with advanced CSCC received cemiplimab 600 mg intravenously Q4W for up to 48 weeks. Tumor measurements were recorded every 8 weeks. The primary endpoint was objective response rate by independent central review. RESULTS: Sixty-three patients with advanced CSCC were treated with cemiplimab.

Mar 1, 2024 | jitc.bmj.com | Danny Rischin |Nicole Basset-Seguin |Dirk Schadendorf |Samantha Bowyer

Clinical/translational cancer immunotherapy High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Mar 1, 2024 | jitc.bmj.com | Dirk Schadendorf |Jason Luke |Paolo A Ascierto |Georgina V. Long

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.